The adjusted multivariate Cox proportional hazard analysis on PD-L1 positive (≥1%) patients with advanced or metastatic NSCLC receiving first-line anti-PD-1 treatment indicated a statistically significant 75% reduction in the adjusted hazard of death (adjusted hazard ratio—aHR: 0.25, 95%CI: 0.11–0.60, p = 0.002; adjusted p = 0.015) when abnobaViscum® therapy was added, as outlined in Table 6. The gene discussed is CD274; the disease is non-small cell lung carcinoma.